Title
Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease
Phase
Phase 2Lead Sponsor
Shanghai Greenvalley Pharmaceutical Co., Ltd.Study Type
InterventionalStatus
Completed Results PostedIndication/Condition
Alzheimer Disease Cognitive ImpairmentIntervention/Treatment
sodium oligo-mannurarate ...Study Participants
255The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.
Alzheimer's disease is known for placing a great burden on caregivers which includes social, psychological, physical or economic aspects. Research indicates that the disease is associated with plaques and tangles in the brain. Currently used treatments offer a small symptomatic benefit. No treatments to delay or halt the progression of the disease are, as of yet, available. The investigators suppose sodium oligo-mannurarate capsule to be effective to halt the progression of the disease.
sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
simulant of sodium oligo-mannurarate capsule
Inclusion Criteria: At least primarily educated. Accord with Probable Alzheimer disease of National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association(NINCDS-ADRDA)'s Criteria. 10 points ≤ Minimum Mean-Square Error(MMSE) ≤ 24 points. Hachinski ischemia scale <4 points. Hamilton depression scale ≤10 points. Should have stable accompanying person, or at least contact 2 hours per day, 4 days per week with accompanying person. The accompanying person should help the patient throughout the trial. Signed the information consent form. Exclusion Criteria: Have been in other clinical trials within 30 days before this trial' start. women during pregnancy or lactation. Dementia caused by other diseases. previous nervous system diseases. Abnormal laboratory results. Uncontrolled hypertension. Unstable or serious diseases of heart, lung, liver, kidney and blood. Visual or auditory handicap. Significant focal lesions revealed by electronic computer X-ray tomography(CT) or magnetic resonance imaging(MRI) in one year before enrollment. Alcohol abuse or drug abuse. psychotic, including patients with serious depression. Patients being in drug therapy of Alzheimer disease which cannot be stopped. In treatment of heparin, Polysaccharide sulfate, mannose ester 3 weeks before the recruitment. Investigator consider the patient cannot finish this trial for any reason. Relatives or employees of the investigators, staff of the investigate centers, contract research organization and sponsor.
| Event Type | Organ System | Event Term | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|
Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 is the most popular cognitive testing instrument used in clinical trials. It consists of 12 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. The total score ranges 0-75, the higher score indicates more severity of the disease. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.
Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. The results classified as 7 degrades as: Markedly improved, Moderately improved, Minimally improved, No change, Minimally worse, Moderately worse, and Markedly worse.
Alzheimer's Disease Cooperative Study/Activities of Daily (ADCS-ADL) is a scale assessed the daily activties of AD patients after interviewed the caregiver. The scale mainly assess the eating, walking, writing, bathing and reading, et al of the subject. The total score ranges 0-78, the higher score indicate improvement in daily activities. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a positive change represents an improvement.
Neuropsychiatric Inventory (NPI) is a scale to obtain information on the presence of psychopathology in patient with brain disorders. The NPI was developed for application to patients with AD and other dementias, but it may be useful in the assessment of behavioral changes in other conditions. Twelve behavioral areas included in the NPI will be assessed in this trial: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety and elation/euphoria, et al. The total score ranges 0 to 120, the higher score indicates worse state of the AD patient. Change after 24wks treatmnt was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.
